Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance

Transplantation

Volumn 82, Issue 1, 2006, Pages 17-22

  Lieberthal, Wilfred ^a,d   Fuhro, Robert ^b   Andry, Christopher ^b   Patel, Vimal ^c   Levine, Jerrold S ^c  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

Acute renal failure; Delayed graft function; Proliferation; Rapamycin

Indexed keywords

RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; S6 KINASE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; KIDNEY ARTERY STENOSIS; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CONVALESCENCE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL PROLIFERATION; DRUG RESISTANCE; GLOMERULAR FILTRATION RATE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES, PROXIMAL; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 33747472922     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000225772.22757.5e     Document Type: Article

References (35)

1. Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc 2003; 35(3 Suppl): 18S.
2. Morice WG, Wiederrecht G, Brunn GJ, et al. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268(30): 22737.
3. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc 2003; 35(3 Suppl): 227S.
4. Fuller TF, Freise CE, Serkova N, et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003; 76(11): 1594.
5. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16): 1926.
6. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54(5): 815.
7. Gagnon A, Lau S, Sorisky A. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J Cell Physiol 2001; 189(1): 14.
8. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Faseb J 2002; 16(8): 771.
9. Zhu J, Wu J, Frizell E, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117(5): 1198.
10. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281(4): F693.
11. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93(5): 2175.
12. Safirstein R. Renal regeneration: reiterating a developmental paradigm. Kidney Int 1999; 56(4): 1599.
13. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14 Suppl 1: S55.
14. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14(4): 1037.
15. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3(4): 416.
16. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15(1): 228.
17. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67(7): 1036.
18. Kuypers DRJ. Benefit-risk assessment of Sirolimus in renal transplantation. Drug Safety 2005; 28: 153.
19. Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000; 14(6): 550.
20. Lieberthal W. Effects of atrial natriuretic factor in ischemic renal injury: studies in the isolated erythrocyte-perfused rat kidney. Clin Res 1991; 39(2): 157.
21. Thompson A, Valeri CR, Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am J Physiol 1995; 269 (2 Pt 2): H743.
22. Racusen LC. Epithelial cell shedding in acute renal injury. Clin Exp Pharmacol Physiol 1998; 25(3- 4): 273.
23. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 2004; 66(5): 1805.
24. Sheridan AM, Schwartz JH, Kroshian VM, et al. Renal mouse proximal tubular cells are more susceptible than MDCK cells to chemical anoxia. Am J Physiol 1993; 265(3 Pt 2): F342.
25. Sheridan AM, Fitzpatrick S, Wang C, et al. Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells. Kidney Int 1996; 49(1): 88.
26. Levine JS, Koh JS, Triaca V, Lieberthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol 1997; 273(4 Pt 2): F575.
27. Sinha D, Bannergee S, Schwartz JH, et al. Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. J Biol Chem 2004; 279(12): 10962.
28. Sinha D, Wang Z, Ruchalski KL, et al. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am J Physiol Renal Physiol 2005; 288(4): F703.
29. Sinha D, Wang Z, Price VR, et al. Chemical anoxia of tubular cells induces activation of c-Src and its translocation to the zonula adherens. Am J Physiol Renal Physiol 2003; 284(3): F488.
30. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16(12): 1472.
31. Fruman DA, Wood MA, Gjertson CK, et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1995; 25(2): 563.
32. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270(46): 27531.
33. Shima H, Pende M, Chen Y, et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. Embo J 1998; 17(22): 6649.
34. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2(3): 222.
35. Noh W-C, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clinical Cancer Research 2004; 10: 1013.